Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

Abstract Eph receptors have emerged as targets for therapy in both neoplastic and non-neoplastic disease, however, particularly in non-neoplastic diseases, redundancy of function limits the effectiveness of targeting individual Eph proteins. We have shown previously that a soluble fusion protein, wh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cassandra L. Pegg, Leanne T. Cooper, Jing Zhao, Michael Gerometta, Fiona M. Smith, Michael Yeh, Perry F. Bartlett, Jeffrey J. Gorman, Andrew W. Boyd
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/8eef0bce7cd74492b8bf629ada41ee50
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares